StockData
GENELUX Corp logo

GENELUX Corp (GNLX) shareholders

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.00+0.08 (+4.17%)

Close on Nov 17, 2026Market cap $90.49MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
21.7%
10M of 45M shares
Institutional holders
72
11 new, 10 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 24 sales
Net sold $340.71K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
4,223,2779.99%13G (passive)Sep 30, 2025
Aladar Szalay2,834,4656.20%13G (passive) amendmentSep 30, 2026
Highbridge Capital Management, LLC2,500,0006.80%13G (passive)Sep 30, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GNLXValueChange% of portfolio
Woodward Diversified Capital, LLC2,262,1085.00%$6.81M+144,9253.00%
Vanguard Capital Management LLC1,677,7243.71%$5.05M−17,7560.00%
Bleichroeder LP1,380,6663.05%$4.16M–0.74%
BlackRock, Inc.439,6020.97%$1.32M+33,7300.00%
Geode Capital Management, LLC439,2130.97%$1.32M−14,5480.00%
CM Management, LLC400,0000.88%$1.20M+150,0000.80%
Bank Of America Corp /De/328,8030.73%$989.70K+4,9380.00%
Vanguard Fiduciary Trust Co236,3440.52%$711.40K−15,2660.00%
Flputnam Investment Management Co231,4050.51%$696.53K−49,4990.01%
Global Retirement Partners, LLC227,8540.50%$685.84KNew0.01%
LPL Financial LLC157,8570.35%$475.15K+18,8160.00%
State Street Corp145,8500.32%$439.01K–0.00%
Provident Wealth Management, LLC144,9080.32%$436.17K−10,7620.11%
LifeSteps Financial, Inc.121,9650.27%$367.12K+3,1030.17%
Osaic Holdings, Inc.121,9580.27%$367.09K+2,9500.00%
Renaissance Technologies LLC105,2290.23%$316.74K+93,0290.00%
Northern Trust Corp89,2790.20%$268.73K−75,1770.00%
Citadel Advisors LLC85,4810.19%$257.30KNew0.00%
Morgan Stanley83,5430.18%$251.46K−4,5050.00%
SteelPeak Wealth, LLC75,8950.17%$228.44K+15,0000.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267210M21.7%11 / 1915 / 101M1M
Q1 2026719M20.6%12 / 1614 / 173M1M
Q4 2025789M20.2%22 / 2012 / 12M0M
Q3 2025577M16.5%6 / 215 / 101M1M
Q2 2025617M16.3%7 / 1911 / 211M1M
Q1 2025757M16.1%26 / 2112 / 83M0M
Q4 2024585M10.8%9 / 1120 / 71M1M
Q3 2024575M11.6%5 / 1717 / 201M2M
Q2 2024737M15.7%26 / 1520 / 203M2M
Q1 2024676M13.6%17 / 2314 / 91M1M
Q4 2023616M13.0%13 / 279 / 82M0M
Q3 2023564M9.4%25 / 261 / 44M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

18 funds held GNLX in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GNLXValue% of fundAs of
Vanguard Total Stock Market Index Fund1,193,6262.64%$3.59M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund467,3691.03%$1.41M0.00%Jun 30, 2026
Fidelity Extended Market Index Fund211,0750.47%$643.78K0.00%May 31, 2026
iShares Micro-Cap ETF138,0460.31%$415.52K0.03%Jun 30, 2026
Fidelity Total Market Index Fund62,1370.14%$189.52K0.00%May 31, 2026
Fidelity Series Total Market Index Fund58,2980.13%$177.81K0.00%May 31, 2026
Goldman Sachs Absolute Return Tracker Fund34,3230.08%$103.31K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund26,0330.06%$79.40K0.00%May 31, 2026
Schwab Total Stock Market Index Fund25,0000.06%$73.50K0.00%Jul 31, 2026
Vanguard Institutional Total Stock Market Index Fund16,7290.04%$50.35K0.00%Jun 30, 2026
1290 VT Micro Cap Portfolio9,2990.02%$27.99K0.01%Jun 30, 2026
Victory Extended Market Index Fund4,6290.01%$13.61K0.00%Jul 31, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND2280.00%$6700.00%Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund-300-0.00%-$903-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Yong YuChief Scientific Officer258,0200.57%Nov 5, 2026
Thomas ZindrickPresident and CEO1,423,3383.15%Nov 5, 2026
Joseph CappelloChief Technical Officer317,8120.70%Nov 5, 2026
Eric GroenGeneral Counsel233,9570.52%Jun 18, 2026
Matthew PulisicChief Financial Officer278,9060.62%Jun 18, 2026
Ralph SmallingHead of Regulatory67,6110.15%Jun 4, 2026
Jason LittenChief Medical Officer––Jan 7, 2026
Sean RyderGeneral Counsel47,6210.11%May 13, 2025
Lourie S. ZakChief Financial Officer82,4520.18%Dec 20, 2024
John W. SmitherDirector91,4030.20%Jul 2, 2026
Mary MirabelliDirector102,6930.23%Jun 18, 2026
John ThomasDirector501,1931.11%Jun 18, 2026
James L. TyreeDirector96,4830.21%Jun 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Joseph Cappello
Chief Technical Officer
Nov 3, 2026Sale−668$2.04$1.36K317,812
Thomas Zindrick
President and CEO
Nov 3, 2026Sale−3,089$2.05$6.32K1,223,338
Yong Yu
Chief Scientific Officer
Nov 3, 2026Sale−668$2.01$1.34K258,020
Yong Yu
Chief Scientific Officer
Aug 31, 2026Sale−9,683$2.75$26.63K258,688
Joseph Cappello
Chief Technical Officer
Aug 31, 2026Sale−10,257$2.74$28.10K318,480
Thomas Zindrick
President and CEO
Aug 31, 2026Sale−34,463$2.67$92.02K1,226,427
Yong Yu
Chief Scientific Officer
Aug 4, 2026Sale−653$2.94$1.92K268,371
Joseph Cappello
Chief Technical Officer
Aug 4, 2026Sale−653$2.95$1.93K328,737
Thomas Zindrick
President and CEO
Aug 4, 2026Sale−3,023$2.95$8.92K1,260,890
John W. Smither
Director
Jul 1, 2026Sale−12,000$2.91$34.92K91,403
Matthew Pulisic
Chief Financial Officer
Jun 16, 2026Award+278,906––278,906
Thomas Zindrick
President and CEO
Jun 16, 2026Award+730,601––1,263,913
Joseph Cappello
Chief Technical Officer
Jun 16, 2026Award+174,841––329,390
James L. Tyree
Director
Jun 16, 2026Award+28,409––96,483
Yong Yu
Chief Scientific Officer
Jun 16, 2026Award+119,318––269,024
John Thomas
Director
Jun 16, 2026Award+28,409––501,193
Eric Groen
General Counsel
Jun 16, 2026Award+233,957––233,957
John W. Smither
Director
Jun 16, 2026Award+28,409––103,403
Mary Mirabelli
Director
Jun 16, 2026Award+28,409––102,693
Ralph Smalling
Head of Regulatory
Jun 3, 2026Sale−192$2.93$56367,611
John Thomas
Director
Jun 1, 2026Sale(10b5-1 plan)−10,000$2.98$29.80K472,784
Joseph Cappello
Chief Technical Officer
May 11, 2026Sale−605$2.97$1.80K154,549
Thomas Zindrick
President and CEO
May 11, 2026Sale−2,798$2.94$8.23K532,051
Yong Yu
Chief Scientific Officer
May 11, 2026Sale−605$2.97$1.80K149,706
Ralph Smalling
Head of Regulatory
May 11, 2026Sale−270$2.98$80567,803
Ralph Smalling
Head of Regulatory
Mar 25, 2026Sale−240$2.51$60268,073
Thomas Zindrick
President and CEO
Mar 24, 2026Sale−3,582$2.42$8.67K534,849
Joseph Cappello
Chief Technical Officer
Mar 24, 2026Sale−906$2.42$2.19K155,154
Yong Yu
SVP, Clinical Development
Mar 24, 2026Sale−906$2.42$2.19K144,938
Ralph Smalling
Head of Regulatory
Mar 24, 2026Sale−345$2.42$83568,313
John Thomas
Director
Mar 2, 2026Sale(10b5-1 plan)−10,000$2.90$29.00K482,784
Ralph Smalling
Head of Regulatory
Dec 5, 2025Sale−165$4.69$77468,658
John Thomas
Director
Dec 1, 2025Sale(10b5-1 plan)−10,000$5.00$50.00K492,784
Thomas Zindrick
President and CEO
Nov 17, 2025Sale−4,509$5.37$24.21K538,431
Joseph Cappello
Chief Technical Officer
Nov 17, 2025Sale−973$5.37$5.23K156,060
Yong Yu
SVP, Clinical Development
Nov 17, 2025Sale−973$5.37$5.23K145,844
Ralph Smalling
Head of Regulatory
Nov 17, 2025Sale−343$5.37$1.84K68,823
Ralph Smalling
Head of Regulatory
Sep 3, 2025Sale−580$3.36$1.95K69,166
Ralph Smalling
Head of Regulatory
Sep 1, 2025Award+10,000––70,990
Ralph Smalling
Head of Regulatory
Aug 27, 2025Award+26,230––60,990
Mary Mirabelli
Director
Aug 27, 2025Award+22,283––73,284
John W. Smither
Director
Aug 27, 2025Award+22,283––74,994
James L. Tyree
Director
Aug 27, 2025Award+22,283––68,074
Thomas Zindrick
President and CEO
Aug 27, 2025Award+361,200––554,161
Yong Yu
SVP, Clinical Development
Aug 27, 2025Award+101,480––150,036
John Thomas
Director
Aug 27, 2025Award+22,283––502,784
Joseph Cappello
Chief Technical Officer
Aug 27, 2025Award+107,500––159,766
Thomas Zindrick
President and CEO
Aug 21, 2025Sale−12,673$3.33$42.20K542,940
Joseph Cappello
Chief Technical Officer
Aug 21, 2025Sale−1,463$3.36$4.92K157,033
Joseph Cappello
Chief Technical Officer
Aug 21, 2025Sale−1,270$3.33$4.23K158,496
Yong Yu
SVP, Clinical Development
Aug 21, 2025Sale−3,219$3.36$10.82K146,817
Ralph Smalling
Head of Regulatory
Aug 21, 2025Sale−1,244$3.36$4.18K69,746
John Thomas
Director
Jun 6, 2025Gift−25,000––480,501
Yong Yu
VP, Clinical Trial Operations
May 12, 2025Sale−5,579$2.92$16.29K47,640
Thomas Zindrick
President and CEO, Director
May 12, 2025Sale−10,764$2.92$31.43K191,447
Ralph Smalling
Head of Regulatory
May 12, 2025Sale−1,259$2.92$3.68K34,760
Sean Ryder
General Counsel
May 12, 2025Sale−4,475$2.92$13.07K47,621
Joseph Cappello
VP, Pharmaceutical Development
May 12, 2025Sale−4,737$2.92$13.83K52,266
Joseph Cappello
VP, Pharmaceutical Development
Mar 14, 2025Award+13,350––57,003
Yong Yu
VP, Clinical Trial Operations
Mar 14, 2025Award+13,350––53,219

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
10.85%
5M shares short
Days to cover
8.3
At 1M shares a day
Change since last report
-2.4%
From 5M shares
Short volume, 20 days
35.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Genelux's stock actually held short. Settlement fails (shares not delivered on time) peaked at 27,279 shares on Sep 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
John W. Smither
Director
Jul 1, 202612,000$34.90KJul 1, 2026Restricted Stock
Johnny Thomas
Officer
Jun 1, 202610,000$30.50KJun 1, 2026Founders Shares
Johnny Thomas
Officer
Mar 2, 202610,000$29.80KMar 2, 2026Founders Shares
Johnny Thomas
Director
Dec 1, 202510,000$55.60KDec 1, 2025Founders Shares
James L. Tyree
Director
Dec 30, 20243,460$8.51KDec 30, 2024Restricted stock vesting under a registered plan
James L. Tyree
Director
Sep 11, 20241,730$4.34KSep 11, 2024Restricted Stock Units
Szalay 2010 Retained Annuity Trust
10% Stockholder
Sep 6, 2024140,000$392.00KSep 9, 2024Irrevocable Grant
Szalay 2010 Retained Annuity Trust
10% Stockholder
Aug 22, 2024400,000$872.00KAug 23, 2024Irrevocable Grant
Szalay 2010 Retained Annuity Trust
10% Stockholder
Apr 15, 2024494,744$2.10MApr 15, 2024Irrevocable Grant
Szalay 2010 Retained Annuity Trust
10% Stockholder
Apr 11, 2024494,744$2.10MApr 15, 2024Private Placement
Yong Yu
Officer
Dec 15, 202332,535$428.18KDec 15, 2023Restricted stock vesting under a registered plan
Johnny Thomas
Director
Dec 13, 20239,000$120.39KDec 13, 2023Restricted stock vesting under a registered plan
James L. Tyree
Officer
Dec 13, 20239,000$118.97KDec 13, 2023Restricted stock vesting under a registered plan
Yong Yu
Officer
Dec 7, 202336,800$436.00KDec 7, 2023Restricted stock vesting under a registered plan
Yong Yu
Officer
Nov 17, 202336,800$479.14KNov 17, 2023Restricted stock vesting under a registered plan

See a number that looks wrong?